联系客服

600750 沪市 江中药业


首页 公告 600750:江中药业2021年第三季度报告

600750:江中药业2021年第三季度报告

公告日期:2021-10-28

600750:江中药业2021年第三季度报告 PDF查看PDF原文

证券代码:600750                                                证券简称:江中药业
          江中药业股份有限公司

          2021 年第三季度报告

    本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,
不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。
公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务
报表信息的真实、准确、完整。
第三季度财务报表是否经审计
□是 √否
一、 主要财务数据
(一)主要会计数据和财务指标

                                                            单位:元 币种:人民币

                                          本报告期                    年初至报告
 项目                    本报告期      比上年同  年初至报告期末  期末比上年
                                          期增减变                    同期增减变
                                        动幅度(%)                    动幅度(%)

 营业收入              671,621,213.03    16.46    1,937,836,872.68    11.68

 归属于上市公司股东    145,264,068.66    13.45    451,831,116.71      13.51

 的净利润
 归属于上市公司股东

 的扣除非经常性损益    125,433,613.19      8.86    401,763,157.53      5.28

 的净利润


 经营活动产生的现金        不适用        不适用    462,330,380.86    -35.29

 流量净额

 基本每股收益              0.23          15.00          0.72          14.29

 (元/股)

 稀释每股收益              0.23          15.00          0.72          14.29

 (元/股)

 加权平均净资产收益        3.58        增加 0.05      11.19      增加 0.35 个
 率(%)                                  个百分点                      百分点

                                                                      本报告期末
                          本报告期末              上年度末            比上年度末
                                                                      增减变动幅
                                                                          度(%)

 总资产              5,147,517,955.61        4,923,573,835.05          4.55

 归属于上市公司股东    4,085,332,676.23        3,876,867,968.11          5.38

 的所有者权益
注:“本报告期”指本季度初至本季度末 3 个月期间,下同。
(二)非经常性损益项目和金额

                                                            单位:元 币种:人民币

                项目                      本报告期金额      年初至报告期末金额

 非流动性资产处置损益(包括已计提资              -1,024.66          903,921.28
 产减值准备的冲销部分)
 计入当期损益的政府补助(与公司正常

 经营业务密切相关,符合国家政策规            13,322,421.26        32,606,873.62
 定、按照一定标准定额或定量持续享受
 的政府补助除外)
 除同公司正常经营业务相关的有效套期
 保值业务外,持有交易性金融资产、交

 易性金融负债产生的公允价值变动损            14,107,734.87        31,375,979.73
 益,以及处置交易性金融资产、交易性
 金融负债和可供出售金融资产取得的投
 资收益

 对外委托贷款取得的损益                                                32,146.03

 除上述各项之外的其他营业外收入和支          -1,602,418.10          -935,508.80
 出

 其他符合非经常性损益定义的损益项目                                  447,281.06

 减:所得税影响额                              1,666,946.68        3,680,242.63

    少数股东权益影响额(税后)                4,329,311.22        10,682,491.11

                合计                          19,830,455.47        50,067,959.18

年初至报告期末主要经营数据
主营业务分行业、分产品情况

                                                            单位:元 币种:人民币

                                主营业务分行业情况

                                              毛利  营业收入  营业成本  毛利率比
  分行业      营业收入        营业成本      率  比上年增  比上年增  上年增减
                                              (%)  减(%)  减(%)  (%)

                                                                            增加

 医药工业  1,927,234,117.24  650,572,202.56  66.24  11.59    9.62    0.60 个
                                                                          百分点

                                                                            减少

  其他      6,705,295.74    2,357,178.69  64.85  111.06    226.64  12.43 个
                                                                          百分点

                                主营业务分产品情况

                                              毛利  营业收入  营业成本  毛利率比
  分产品      营业收入        营业成本      率  比上年增  比上年增  上年增减
                                              (%)  减(%)  减(%)  (%)

 非处方药                                                                  增加

    类    1,543,406,365.41  479,672,620.32  68.92  12.38    8.80    1.02 个
                                                                          百分点

                                                                            减少

 处方药类  238,110,312.72  92,061,856.73  61.34    0.94      7.10    2.22 个
                                                                          百分点

 大健康产                                                                  增加

 品及其他  152,422,734.85  81,194,904.20  46.73  25.89    20.54    2.36 个
                                                                          百分点

                                                                            增加

  合计    1,933,939,412.98  652,929,381.25  66.24  11.77    9.88    0.58 个
                                                                          百分点

主营业务分地区情况

                                                          单位:元 币种:人民币

          地区                    营业收入            营业收入比上年增减(%)

          华北                        382,986,489.04                      -1.73

          华东                        580,159,751.22                      12.87

          华南                        493,724,633.85
[点击查看PDF原文]